A Study of LY3457263 in Obese Participants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called LY3457263 together with tirzepatide to see if they are safe and well-tolerated in overweight or obese people. The study will also measure how much of LY3457263 gets into the bloodstream and how long it stays in the body. The trial will last a few months.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study involves evaluating new medications, it's possible that some changes to your current medication regimen might be required. Please consult with the trial coordinators for specific guidance.
How is the drug LY3457263 (Tirzepatide) different from other treatments for type 2 diabetes?
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple doses of LY3457263 in combination with tirzepatide
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3457263
- Placebo
- Tirzepatide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University